Free Trial
NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

Century Therapeutics logo
$0.54 +0.04 (+8.74%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.54 -0.01 (-1.60%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Century Therapeutics Stock (NASDAQ:IPSC)

Key Stats

Today's Range
$0.50
$0.56
50-Day Range
$0.39
$0.77
52-Week Range
$0.34
$3.70
Volume
657,515 shs
Average Volume
409,673 shs
Market Capitalization
$46.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.40
Consensus Rating
Buy

Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

IPSC MarketRank™: 

Century Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 621st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Century Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Century Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Century Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Century Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Century Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Century Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.06% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 7.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Century Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Century Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.06% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 7.40%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Century Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for IPSC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,655.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Century Therapeutics is held by insiders.

  • Percentage Held by Institutions

    50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Century Therapeutics' insider trading history.
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

New “Trump” currency proposed in DC
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Century Therapeutics (IPSC) Receives a Buy from Piper Sandler
See More Headlines

IPSC Stock Analysis - Frequently Asked Questions

Century Therapeutics' stock was trading at $1.01 at the start of the year. Since then, IPSC stock has decreased by 46.2% and is now trading at $0.5437.
View the best growth stocks for 2025 here
.

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its earnings results on Wednesday, March, 19th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $0.67 million. Century Therapeutics had a negative trailing twelve-month return on equity of 61.66% and a negative net margin of 4,837.73%.

Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
3/19/2025
Today
4/20/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.40
High Stock Price Target
$7.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+709.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-136,670,000.00
Net Margins
-4,837.73%
Pretax Margin
-4,869.53%

Debt

Sales & Book Value

Annual Sales
$6.59 million
Price / Cash Flow
N/A
Book Value
$3.06 per share
Price / Book
0.18

Miscellaneous

Free Float
79,247,000
Market Cap
$46.78 million
Optionable
Optionable
Beta
1.83
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IPSC) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners